PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24977346-7 2014 Inhibition of Akt enhanced the relaxation and cGMP elevation of porcine pulmonary arteries induced by DETA NONOate or sodium nitroprusside, which was prevented by zaprinast, a specific inhibitor of PDE5. zaprinast 163-172 phosphodiesterase 5A Homo sapiens 198-202 22028410-6 2012 The PDE5i zaprinast significantly increased prostate strip relaxation to the nitric oxide donor sodium nitroprusside (SNP) in control but not castrated rats. zaprinast 10-19 phosphodiesterase 5A Homo sapiens 4-8 23986226-5 2013 Since inhibition of PDE3 enhances ATP release in response to PGI2 analogs, we investigated if the selective PDE5 inhibitors, zaprinast (ZAP) and tadalafil (TAD), would similarly increase cAMP and ATP release from human erythrocytes in response to the same stimulus. zaprinast 125-134 phosphodiesterase 5A Homo sapiens 108-112 24550991-6 2014 Cell proliferation induced by PDE5 inhibitors was dependent on the activation of the mitogen-activated protein kinase (MAPK) and was abolished by inhibitors of MAPK signaling, soluble guanylyl cyclase, and protein kinase G. Moreover, sildenafil neither activated ERK1/2 nor altered p27(Kip1) levels, suggesting the involvement of pathways different from those activated by T0156 or zaprinast. zaprinast 382-391 phosphodiesterase 5A Homo sapiens 30-34 23086989-5 2012 The effect of melatonin on SNP-induced relaxation was abolished in the presence of the PDE5 inhibitors zaprinast and sildenafil. zaprinast 103-112 phosphodiesterase 5A Homo sapiens 87-91 22028410-10 2012 Zaprinast findings strongly suggest a major role for PDE5/cGMP in this signaling cascade. zaprinast 0-9 phosphodiesterase 5A Homo sapiens 53-57 21717503-5 2011 RESULTS: The inhibitory effects of an NO donor (SNAP) and a PDE-5 inhibitor (zaprinast) on spontaneous activity of bladder strips decreased during postnatal development, while an inhibitory effect of 8-bromo-cGMP, which was blocked by a protein kinase G inhibitor, was detected at all ages tested. zaprinast 77-86 phosphodiesterase 5A Homo sapiens 60-65 21791937-4 2012 OBJECTIVES: To determine whether the PDE5 inhibitor, zaprinast, causes dilation in pulmonary and middle cerebral arteries (MCA) of normoxic newborn piglets and those with chronic hypoxia-induced pulmonary hypertension, and to evaluate whether zaprinast alters responses to increased pressure (autoregulatory ability) of the MCA. zaprinast 53-62 phosphodiesterase 5A Homo sapiens 37-41 21791937-11 2012 CONCLUSIONS: Pulmonary artery dilation to zaprinast supports the use of PDE5 inhibitors to treat pulmonary hypertension in neonates. zaprinast 42-51 phosphodiesterase 5A Homo sapiens 72-76 15295092-8 2004 The PDE5 inhibitors dipyridamole and zaprinast, produced qualitatively similar effects but with lower potency. zaprinast 37-46 phosphodiesterase 5A Homo sapiens 4-8 18282775-11 2008 Inhibitor of cGMP-specific PDE5 (zaprinast; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis. zaprinast 33-42 phosphodiesterase 5A Homo sapiens 27-31 16157016-13 2005 CONCLUSIONS: The PDE5 inhibitor zaprinast may selectively increase CBF in the ischemic brain via increased cGMP levels, thus providing a new strategy against acute cerebral infarction. zaprinast 32-41 phosphodiesterase 5A Homo sapiens 17-21 15792963-6 2005 Indeed, at any ANP concentration, the sustained (30 min) [cGMP]i rise is greater in PMVECs than in PAECs, unless PAECs are also treated with the PDE5 inhibitor zaprinast. zaprinast 160-169 phosphodiesterase 5A Homo sapiens 145-149 15567064-2 2005 The cGMP-PDE5 inhibitors Sildenafil and Zaprinast have been demonstrated to potentiate the anti-platelet aggregatory effect of NO donors like sodium nitroprusside (SNP) in vitro but the mechanisms of Sildenafil"s action on the secretory function of human platelets have not been analysed in detail. zaprinast 40-49 phosphodiesterase 5A Homo sapiens 9-13 15571296-3 2004 After six days of incubation in the presence of each specific inhibitor at 10 x IC50 levels a cytostatic and differentiating effect was only observed with the PDE5 inhibitors Zaprinast and MY-5445. zaprinast 175-184 phosphodiesterase 5A Homo sapiens 159-163 10385692-4 1999 Both sildenafil and zaprinast are competitive inhibitors of PDE5, and double-inhibition analysis shows that these two inhibitors added together interact with the catalytic site of PDE5 in a mutually exclusive manner. zaprinast 20-29 phosphodiesterase 5A Homo sapiens 60-64 11969359-7 2002 The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak. zaprinast 132-141 phosphodiesterase 5A Homo sapiens 116-120 14722776-3 2004 This effect of SNP was apparent only in the presence of 50 micro M zaprinast, an inhibitor of the cGMP-specific phosphodiesterase-5 (PDE5). zaprinast 67-76 phosphodiesterase 5A Homo sapiens 133-137 14602552-6 2003 Cilostazol phosphorylated VASP at both Ser157 and Ser239 in a concentration-dependent manner, but EHNA (PDE2 inhibitor), dipyridamole and zaprinast (PDE5 inhibitors) did not. zaprinast 138-147 phosphodiesterase 5A Homo sapiens 149-153 11805217-9 2002 Simultaneous inhibition of PDE5, 6, and 9 (zaprinast), purported to specifically elevate intracellular cGMP, reduced, in a dose-independent manner, IL-6 and TNF-alpha biosynthesis. zaprinast 43-52 phosphodiesterase 5A Homo sapiens 27-41 11388700-8 2001 Thus, the corpus cavernosum PDE5s are very similar among the various species with the only significant difference being their sensitivity to zaprinast. zaprinast 141-150 phosphodiesterase 5A Homo sapiens 28-32 10679826-5 2000 The presence of human PDE5 in this cell line was confirmed by Western blot analysis, using an antibody raised to the bovine enzyme, and by the observation that cGMP hydrolytic activity detected in T84 cell lysates was almost completely inhibited by low concentrations of zaprinast, a specific inhibitor of PDE5. zaprinast 271-280 phosphodiesterase 5A Homo sapiens 22-26 10385692-4 1999 Both sildenafil and zaprinast are competitive inhibitors of PDE5, and double-inhibition analysis shows that these two inhibitors added together interact with the catalytic site of PDE5 in a mutually exclusive manner. zaprinast 20-29 phosphodiesterase 5A Homo sapiens 180-184 10385692-5 1999 After site-directed mutagenesis of each of 23 conserved amino acid residues in the catalytic domain of PDE5, the pattern of changes in the IC50 values for sildenafil or UK-122764 is similar to that found for zaprinast. zaprinast 208-217 phosphodiesterase 5A Homo sapiens 103-107 9922221-9 1999 Increased cyclic guanosine monophosphate levels in these cells provoked by sodium nitroprusside and the PDE5 inhibitor zaprinast reduced the PGE2 synthesis, whereas 15-HETE and IL-8 formation were unchanged. zaprinast 119-128 phosphodiesterase 5A Homo sapiens 104-108 9497379-8 1998 Zaprinast is a potent competitive inhibitor of cGB-PDE, but the key residues for its binding differ significantly from those that bind cGMP. zaprinast 0-9 phosphodiesterase 5A Homo sapiens 47-54 9714779-4 1998 This activity was inhibited by the selective PDE5 inhibitors zaprinast and DMPPO. zaprinast 61-70 phosphodiesterase 5A Homo sapiens 45-49 9723958-6 1998 Nonetheless ANP (10(-9) to 10(-6) M), in the presence of zaprinast, an inhibitor of phosphodiesterase 5 (PDE5), increased fibroblast cyclic GMP levels 3-5 fold in a concentration-dependent manner (P < 0.05). zaprinast 57-66 phosphodiesterase 5A Homo sapiens 105-109 9559913-9 1998 Pretreatment of neutrophils with the PDE3 inhibitor ORG 9935 or the PDE5 inhibitor zaprinast had no effect on IL-8 generation. zaprinast 83-92 phosphodiesterase 5A Homo sapiens 68-72